• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫苗研究中的实验模型:疟疾和利什曼病

Experimental models in vaccine research: malaria and leishmaniasis.

作者信息

Teixeira C, Gomes R

机构信息

Fundação Oswaldo Cruz (FIOCRUZ), Centro de Pesquisas Gonçalo Moniz, Salvador, BA, Brasil.

出版信息

Braz J Med Biol Res. 2013 Feb;46(2):109-16. doi: 10.1590/1414-431x20122460. Epub 2013 Feb 1.

DOI:10.1590/1414-431x20122460
PMID:23369975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3854354/
Abstract

Animal models have a long history of being useful tools, not only to test and select vaccines, but also to help understand the elaborate details of the immune response that follows infection. Different models have been extensively used to investigate putative immunological correlates of protection against parasitic diseases that are important to reach a successful vaccine. The greatest challenge has been the improvement and adaptation of these models to reflect the reality of human disease and the screening of vaccine candidates capable of overcoming the challenge of natural transmission. This review will discuss the advantages and challenges of using experimental animal models for vaccine development and how the knowledge achieved can be extrapolated to human disease by looking into two important parasitic diseases: malaria and leishmaniasis.

摘要

动物模型作为有用的工具已有很长历史,不仅用于测试和筛选疫苗,还有助于了解感染后免疫反应的详细情况。不同的模型已被广泛用于研究针对寄生虫病的假定免疫保护关联因素,这对于成功研发疫苗至关重要。最大的挑战在于改进和调整这些模型以反映人类疾病的实际情况,以及筛选能够克服自然传播挑战的候选疫苗。本综述将通过研究两种重要的寄生虫病:疟疾和利什曼病,来讨论使用实验动物模型进行疫苗研发的优势和挑战,以及所获得的知识如何外推至人类疾病。

相似文献

1
Experimental models in vaccine research: malaria and leishmaniasis.疫苗研究中的实验模型:疟疾和利什曼病
Braz J Med Biol Res. 2013 Feb;46(2):109-16. doi: 10.1590/1414-431x20122460. Epub 2013 Feb 1.
2
Vaccines against tropical parasitic diseases: a persisting answer to a persisting problem.针对热带寄生虫病的疫苗:持久应对持久问题的答案。
Nat Immunol. 2014 May;15(5):403-5. doi: 10.1038/ni.2853.
3
The Delay in the Licensing of Protozoal Vaccines: A Comparative History.原生动物疫苗的许可延迟:比较历史。
Front Immunol. 2020 Mar 6;11:204. doi: 10.3389/fimmu.2020.00204. eCollection 2020.
4
Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.三种抗原性婴儿利什曼原虫聚(A)结合蛋白作为DNA疫苗共同给药可诱导BALB/c小鼠对硕大利什曼原虫感染产生保护作用。
PLoS Negl Trop Dis. 2015 May 8;9(5):e0003751. doi: 10.1371/journal.pntd.0003751. eCollection 2015 May.
5
Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.DNA 和蛋白质利什曼原虫γ-谷氨酰半胱氨酸合成酶疫苗对预防大疱性皮肤利什曼病或墨西哥利什曼原虫感染引起的小鼠皮肤利什曼病的交叉保护作用的比较评估。
Vaccine. 2012 Feb 8;30(7):1357-63. doi: 10.1016/j.vaccine.2011.12.067. Epub 2011 Dec 28.
6
Vaccine candidates for leishmaniasis: a review.利什曼病疫苗候选物:综述。
Int Immunopharmacol. 2011 Oct;11(10):1464-88. doi: 10.1016/j.intimp.2011.05.008. Epub 2011 May 25.
7
Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.III型半胱氨酸蛋白酶对BALB/c小鼠的婴儿利什曼原虫感染具有保护作用,并且在内脏利什曼病患者中具有高度抗原性。
Vaccine. 2008 Oct 29;26(46):5822-9. doi: 10.1016/j.vaccine.2008.08.065. Epub 2008 Sep 18.
8
The challenges on developing vaccine against visceral leishmaniasis.开发抗内脏利什曼病疫苗面临的挑战。
Rev Soc Bras Med Trop. 2016 Jul-Aug;49(4):395-7. doi: 10.1590/0037-8682-0343-2016.
9
Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.不同佐剂增强 78kDa 抗原对小鼠内脏利什曼病的疗效和免疫原性。
Vaccine. 2010 May 21;28(23):4002-12. doi: 10.1016/j.vaccine.2010.01.015. Epub 2010 Jan 19.
10
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.用于人类内脏利什曼病和黑热病后皮肤利什曼病的第三代疫苗:ChAd63-KH的首次人体试验。
PLoS Negl Trop Dis. 2017 May 12;11(5):e0005527. doi: 10.1371/journal.pntd.0005527. eCollection 2017 May.

引用本文的文献

1
Why the Jenner/Pasteur paradigm is insufficient for controlling vector-borne diseases and the role of microbiota-mediated interactions.为什么詹纳/巴斯德范式不足以控制媒介传播疾病以及微生物群介导的相互作用的作用。
Curr Res Parasitol Vector Borne Dis. 2025 Jul 8;8:100291. doi: 10.1016/j.crpvbd.2025.100291. eCollection 2025.
2
A Review of Major Patents on Potential Malaria Vaccine Targets.潜在疟疾疫苗靶点的主要专利综述
Pathogens. 2023 Feb 3;12(2):247. doi: 10.3390/pathogens12020247.
3
An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials.用于临床前红细胞前期疟疾疫苗开发的不断扩展的工具包:连接传统小鼠疟疾模型与人体试验
Future Microbiol. 2016 Dec;11(12):1563-1579. doi: 10.2217/fmb-2016-0077. Epub 2016 Nov 18.
4
Molecular and immunological tools for the evaluation of the cellular immune response in the neotropical monkey Saimiri sciureus, a non-human primate model for malaria research.用于评估新热带猴松鼠猴(疟疾研究的非人灵长类动物模型)细胞免疫反应的分子和免疫学工具。
Malar J. 2015 Apr 18;14:166. doi: 10.1186/s12936-015-0688-1.
5
Challenges in the research and development of new human vaccines.新型人类疫苗研发中的挑战
Braz J Med Biol Res. 2013 Feb;46(2):103-8. doi: 10.1590/1414-431x20131873.

本文引用的文献

1
Immunity to sand fly salivary protein LJM11 modulates host response to vector-transmitted leishmania conferring ulcer-free protection.对沙蝇唾液蛋白 LJM11 的免疫调节可改变宿主对媒介传播的利什曼原虫的反应,从而提供无溃疡的保护。
J Invest Dermatol. 2012 Dec;132(12):2735-43. doi: 10.1038/jid.2012.205. Epub 2012 Jun 28.
2
Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.针对内脏利什曼病的抗利什曼原虫疫苗的制作:合理性、更新和展望。
Curr Opin Microbiol. 2012 Aug;15(4):476-85. doi: 10.1016/j.mib.2012.05.002. Epub 2012 Jun 13.
3
Development of humanized mouse models to study human malaria parasite infection.人源化小鼠模型的开发用于研究人类疟原虫感染。
Future Microbiol. 2012 May;7(5):657-65. doi: 10.2217/fmb.12.27.
4
Vaccines for canine leishmaniasis.犬利什曼病疫苗。
Front Immunol. 2012 Apr 17;3:69. doi: 10.3389/fimmu.2012.00069. eCollection 2012.
5
KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi.KSAC,一种明确的利什曼原虫抗原,加上佐剂,可预防其天然媒介白蛉传播的强毒力的大沙鼠利什曼原虫。
PLoS Negl Trop Dis. 2012;6(4):e1610. doi: 10.1371/journal.pntd.0001610. Epub 2012 Apr 3.
6
The development and clinical evaluation of second-generation leishmaniasis vaccines.第二代利什曼病疫苗的研发与临床评估。
Vaccine. 2012 Jan 5;30(2):134-41. doi: 10.1016/j.vaccine.2011.11.005. Epub 2011 Nov 12.
7
Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy.伯氏疟原虫(Plasmodium berghei)挑战模型比较用于评估红细胞前期疟疾疫苗及其对疫苗效果感知的影响。
Malar J. 2010 May 27;9:145. doi: 10.1186/1475-2875-9-145.
8
A retrospective evaluation of the role of T cells in the development of malaria vaccine.回顾性评估 T 细胞在疟疾疫苗发展中的作用。
Exp Parasitol. 2010 Nov;126(3):421-5. doi: 10.1016/j.exppara.2009.11.009. Epub 2009 Nov 26.
9
What have we learnt from mouse models for the study of malaria?我们从用于疟疾研究的小鼠模型中学到了什么?
Eur J Immunol. 2009 Aug;39(8):2004-7. doi: 10.1002/eji.200939552.
10
Vector transmission of leishmania abrogates vaccine-induced protective immunity.利什曼原虫的媒介传播消除了疫苗诱导的保护性免疫。
PLoS Pathog. 2009 Jun;5(6):e1000484. doi: 10.1371/journal.ppat.1000484. Epub 2009 Jun 19.